We sat down with Lauren Litzinger at Pfizer to discuss virtual monitoring of clinical research sites and studies. We are seeing a shift in how monitoring is being conducted in the wake of COVID-19 and the requirement for so many activities to go virtual and digital. Monitoring is no exception. Various options for data verification and review are discussed, as well as what are some of the changes being seen at the pharmaceutical sponsor level.